Incyte’s Tafasitamab Combo Shows 25% PFS Improvement in High-Risk DLBCL

Event summary

  • Incyte’s Phase 3 frontMIND trial showed Tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R-CHOP reduced risk of disease progression or death by 25% in high-risk DLBCL patients.
  • The trial met its primary endpoint of progression-free survival (PFS) with a hazard ratio of 0.75 (P=0.0194).
  • Results were presented at the 2026 ASCO Annual Meeting and published in The Lancet.
  • Tafasitamab combination therapy improved 2-year PFS by 8.2% and 3-year PFS by 6.6% compared to R-CHOP alone.
  • Incyte plans to submit global regulatory applications for the Tafasitamab combination as a first-line treatment for DLBCL.

The big picture

Incyte’s positive frontMIND trial results position Tafasitamab as a potential new standard of care for high-risk DLBCL, a market that has seen limited innovation for decades. The trial’s success underscores the growing importance of combination therapies in oncology, particularly for aggressive lymphomas. Incyte’s ability to leverage these results for regulatory approvals and market adoption will be critical in maintaining its competitive edge in the hematology space.

What we're watching

Regulatory Approval
The pace at which global regulatory agencies will approve Tafasitamab combination therapy for first-line DLBCL treatment.
Market Adoption
How quickly oncologists will adopt Tafasitamab combination therapy as a new standard of care for high-risk DLBCL patients.
Competitive Dynamics
Whether Incyte can sustain its lead in the DLBCL treatment space amid potential competitive responses from other biopharmaceutical companies.

Related topics

Oncology